Description

Pembrolizumab is a monoclonal antibody used in cancer immunotherapy. It works by inhibiting the programmed cell death protein 1 (PD-1) pathway, thereby enhancing the immune response against cancer cells.

Interpreter Notes

Interpreters should be aware that 'Pembrolizumab' may be referred to in various contexts, such as oncology or immunotherapy. It is important to maintain a formal register and avoid colloquial terms. Stick to the glossary term to ensure clarity in clinical discussions.

Example Sentences

EN: The oncologist recommended Pembrolizumab as a treatment option for the patient's advanced melanoma.

ES: El oncólogo recomendó Pembrolizumab como una opción de tratamiento para el melanoma avanzado del paciente.

Common Interpreter Mistakes

Confusing Pembrolizumab with similar immunotherapy drugs; mispronouncing the drug name; using informal language when discussing treatment options.